Home
About
Overview
Sharing Data
ORCID
Help
History (32)
ATP requirements and small interfering RNA structure in the RNA interference pathway.
IL-4 suppresses dendritic cell response to type I interferons.
Cartilage hair hypoplasia: characteristics and orthopaedic manifestations.
Development and Implementation of a Collaborative Team Care Model for Effective Insulin Use in an Academic Medical Center Primary Care Network.
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
See All 32 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
Paul B, Rodriguez C, Usmani SZ. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy. Drugs. 2022 Apr; 82(6):613-631.
View in:
PubMed
subject areas
B-Cell Maturation Antigen
Biological Therapy
Humans
Immunotherapy, Adoptive
Multiple Myeloma
Neoplasm Recurrence, Local
Standard of Care
authors with profiles
Saad Usmani MD